ARTICLE | Clinical News
Nexavar meets PFS endpoint in Phase III thyroid cancer trial
January 4, 2013 12:51 AM UTC
Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) and partner Bayer AG (Xetra:BAYN) said twice-daily oral Nexavar sorafenib met the primary endpoint of improving progression-free survival (PFS) vs. placebo in t...